Fig. 5

Bufalin inhibits CRC cell growth via an antiangiogenic mechanism in vivo. a Scheme and schedule of imaging and treatments. b Tumour volumes from day 0 to day 28. c Tumour growth was visualized by an in vivo imaging system from day 7 to day 28. d Tumour weights and images. e IHC analysis of CD31 and Ki67 in tumours. f VEGF expression level in serum. g Immunofluorescence analysis of CD31 and p-STAT3 in tumours. **P < 0.01, ***P < 0.001. Data are shown as mean s.e.m. IHC, immunohistochemistry